Drug Trial Radar · NCT07493304
Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,600
Planned (sponsor's estimate)
Start
Aug 26, 2026
Primary completion
Jul 18, 2031
Study completion Jul 18, 2031
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Mar 25, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is researching an experimental drug called REGN7508 (called "study drug") and will consist of 2 parts: Part 1 and Part 2. The study is focused on participants with or without cancer who develop blood clots in certain veins (called Deep Vein Thrombosis \[DVT\]) that block blood flow (Part 1) or focused on participants with cancer who develop blood clots in certain veins (DVT) or the lungs (also called Pulmonary Embolism \[PE\]) (Part 2). The aim of the study is to see how safe and effective the study drug is at treating and preventing further blood clots in participants with or without cancer (Part 1) or in participants with cancer (Part 2) compared with another treatment (apixaban). The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Conditions
- Venous Thromboembolism (VTE)
Interventions
REGN7508Drug
Administered per the protocol
ApixabanDrug
Administered per the protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of Treatment-Emergent Adverse Events (TEAEs)Time frame: Approximately 6 months
- Severity of TEAEsTime frame: Approximately 6 months
- Time-to-first event of centrally adjudicated recurrent VTE [DVT (symptomatic or asymptomatic [proximal] or Non-fatal PE (symptomatic or asymptomatic [in a segmental or larger pulmonary artery] )or VTE-related death)]Time frame: Up to approximately 3.5 years
- Time-to-first event of centrally adjudicated International Society of Thrombosis and Hemostasis (ISTH)-defined major bleeding or Clinically Relevant Non-Major (CRNM) bleedingTime frame: Up to approximately 3.5 years
Locations
14 sites in 5 countries. Site status is shown where the registry gives one.
Bioresearch Partner- Hialeah Hospital
Hialeah, Florida · Withdrawn
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
El Paso Medical Research Institute (Medresearch Inc)
El Paso, Texas · Withdrawn
Arensia Exploratory Medicine, Multiprofile Hospital for Active Treatment Sveta Sofia
Sofia, Bulgaria · Recruiting
Tokai University Hospital
Isehara-Shi, Kanagawa, Japan · Recruiting
Tokyo Medical University Hospital
Shinjuku, Tokyo, Japan · Recruiting
Yamaguchi University Hospital
Ube, Yamaguchi, Japan · Recruiting
Institute of Oncology Bucharest
Bucharest, Bucharest, Romania · Recruiting
Arensia Exploratory Medicine, The Oncology Institute "Prof. Dr. Ion Chiricuta"
Cluj-Napoca, Cluj, Romania · Recruiting
Inje University, Haeundae Paik Hospital
Busan, South Korea · Recruiting
Yonsei University Health System, Severance Hospital
Seoul, South Korea · Recruiting
Samsung Medical Center
Seoul, South Korea · Recruiting
Seoul National University Hospital
Seoul, South Korea · Recruiting
Yonsei University Health System, Yongin Severance Hospital
Yongin-si, Gyeonggi-do, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.